SCHEMBL20565137

SCHEMBL20565137

CCOC(=O)C(C)(C(=O)OC(C)(C)C)C1CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ALDH1A1 P00352 2/20 0.37
TSHR P16473 2/20 0.37
CYP4F2 P78329 3/20 0.35
CYP4A11 Q02928 3/20 0.35
DGAT1 O75907 1/20 0.34
PKM P14618 3/20 0.33
PPM1B O75688 1/20 0.33
PTPN1 P18031 1/20 0.33
PPP1CC P36873 1/20 0.33
MMP8 P22894 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ABCB11 O95342 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
HTR2A P28223 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9219742 0.91 CYP4F2 (0.40) MEN1KMT2AALDH1A1TSHRCYP4F2
SCHEMBL10708309 0.84 CYP4F2 (0.36) MEN1KMT2AALDH1A1TSHRCYP4F2
SCHEMBL10486329 0.83 CYP4F2 (0.38) MEN1KMT2AALDH1A1TSHRCYP4F2
SCHEMBL10028034 0.83 ALDH1A1 (0.39) MEN1KMT2AALDH1A1CYP4F2CYP4A11
SCHEMBL4418141 0.81 ALDH1A1 (0.38) MEN1KMT2AALDH1A1TSHRCYP4F2
SCHEMBL16732122 0.81 ALDH1A1 (0.41) ALDH1A1CYP4F2CYP4A11KDM4ETHRB
SCHEMBL28077248 0.79 DGAT1 (0.45) DGAT1
SCHEMBL15910254 0.79 CYP4F2 (0.39) MEN1KMT2ACYP4F2CYP4A11PKM
SCHEMBL11017860 0.77 CYP1A2 (0.42) MEN1KMT2AALDH1A1CYP4F2CYP4A11
SCHEMBL10707614 0.77 CYP1A2 (0.42) MEN1KMT2AALDH1A1CYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119285572-A Kinase inhibitors and uses thereof 戴纳立制药公司 2025-01-10 CN disclosed
US-20250011338-A1 Kinase Inhibitors and Uses Thereof DENALI THERAPEUTICS INC. (US) 2025-01-09 US disclosed
CN-119264073-A Kinase inhibitors and uses thereof 戴纳立制药公司 2025-01-07 CN disclosed
US-12129263-B2 Kinase inhibitors and uses thereof DENALI THERAPEUTICS INC. (US) 2024-10-29 US disclosed
CN-110913858-B Kinase inhibitors and uses thereof 戴纳立制药公司 2024-09-24 CN disclosed
US-20220041620-A1 Kinase Inhibitors and Uses Thereof DENALI THERAPEUTICS INC. (US) 2022-02-10 US disclosed
US-11203600-B2 Kinase inhibitors and uses thereof DENALI THERAPEUTICS INC. (US) 2021-12-21 US disclosed
EP-3624797-A1 KINASE INHIBITORS AND USES THEREOF Denali Therapeutics Inc. (US) 2020-03-25 EP disclosed
CN-110913858-A Kinase inhibitors and uses thereof 戴纳立制药公司 2020-03-24 CN disclosed
US-20200087319-A1 Kinase Inhibitors and Uses Thereof DENALI THERAPEUTICS INC. (US) 2020-03-19 US disclosed
WO-2018213632-A1 KINASE INHIBITORS AND USES THEREOF DENALI THERAPEUTICS INC. (US) 2018-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011338-A1 Kinase Inhibitors and Uses Thereof MAP3K20, MAP3K6, MAP3K19 NFKB1 1212/4885NFKB2 1061/4885RELA 1269/4885
US-20200087319-A1 Kinase Inhibitors and Uses Thereof MAP3K20, MAP3K6, MAP3K19 NFKB1 1212/4885NFKB2 1061/4885RELA 1269/4885
US-11203600-B2 Kinase inhibitors and uses thereof MAP3K20, MAP3K6, MAP3K19 NFKB1 1212/4885NFKB2 1061/4885RELA 1269/4885
US-20220041620-A1 Kinase Inhibitors and Uses Thereof MAP3K20, MAP3K6, MAP3K19 NFKB1 1212/4885NFKB2 1061/4885RELA 1269/4885
US-12129263-B2 Kinase inhibitors and uses thereof MAP3K20, MAP3K6, MAP3K19 NFKB1 1212/4885NFKB2 1061/4885RELA 1269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.